ClinicalTrials.gg
CompletedNCT01539512Updated May 14, 2019Results posted

A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Completed at 72 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 25
220 · median 102
Started
2012
with 4 others
Phase 3
8 of 25
none open now
Registered
6th of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for chronic lymphocytic leukemia (CLL). Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib plus rituximab or placebo plus rituximab. Participants who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active idelalisib therapy in the extension study, GS-US-312-0117.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
  • CAL-101
  • GS 1101
  • PI3K
  • GS-US-312-0117
  • idelalisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion:

  • Adult subjects with previously treated recurrent CLL who have measurable lymphadenopathy
  • Require therapy for CLL
  • Have experienced CLL progression \< 24 months since the completion of the last prior therapy
  • Currently not sufficiently fit to receive cytotoxic therapy because of chemotherapy-induced bone marrow damage or comorbidities.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
220 participants (actual)

Study arms

  • Active comparator
    Idelalisib + rituximab

    Participants will receive idelalisib plus rituximab

    Drug: Idelalisib · Drug: Rituximab

  • Placebo comparator
    Placebo + rituximab

    Participants will receive placebo to match idelalisib plus rituximab

    Drug: Rituximab · Drug: Placebo to match idelalisib

Interventions

  • Idelalisib 150 mg tablet administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL 101

  • Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m\^2, and 500 mg/m\^2 thereafter

    Also known as: Rituxan®

  • DrugPlacebo to match idelalisib

    Placebo to match idelalisib administered orally twice daily

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.

    Time frame: Up to 17 months

Secondary outcomes

  1. Overall Response Rate

    Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.

    Time frame: Up to 17 months

  2. Lymph Node Response Rate

    Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.

    Time frame: Up to 17 months

  3. Overall Survival

    Overall survival was defined as the interval from randomization to death from any cause.

    Time frame: Up to 17 months

  4. Complete Response Rate

    Complete response rate was defined as the percentage of participants who achieved a complete response.

    Time frame: Up to 17 months

07

Results

Posted Oct 16, 2014
Limitations and caveats
Following a recommendation by an independent Data Monitoring Committee (DMC), the study was stopped early due to highly statistically significant results for the primary efficacy endpoint of progression-free survival.

Participant flow

Participants were enrolled at a total of 53 study sites in the United States and Europe. The first participant was screened on 03 April 2012. The last study visit occurred on 20 April 2014.

Participant flow — Overall Study
MilestoneIdelalisib + RituximabPlacebo + Rituximab
Started110110
Completed8797
Not completed2313
Withdrew: Adverse event97
Withdrew: Physician decision11
Withdrew: Withdrawal by subject125
Withdrew: Richter's transformation10

Outcome measures

PrimaryProgression-Free Survival

Progression-free survival was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL.

Time frame:
Up to 17 months
Reported as:
Median · months
Progression-Free Survival
monthsIdelalisib + RituximabPlacebo + Rituximab
Progression-Free SurvivalNA (10.7 to NA)5.5 (3.8 to 7.1)
Statistical analysis
  • Idelalisib + Rituximab vs Placebo + Rituximab · Log Rank · p = < 0.0001 · Hazard ratio (hr): 0.18 · 95% CI 0.10 to 0.32P-value is from stratified log-rank test, adjusted for randomization stratification factors.
SecondaryOverall Response Rate

Overall response rate was defined as the percentage of participants who achieved a best overall response of complete response or partial response. Complete response was defined as no lymphadenopathy, hepatomegaly, splenomegaly; normal complete blood count; confirmed by bone marrow aspirate \& biopsy. Partial response was defined as \>1 of the following criteria: a 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver size, spleen size; plus ≥ 1 of the following: ≥ 1500/μL absolute neutrophil count, \> 100000/μL platelets, \> 11.0 g/dL hemoglobin or 50% improvement for either of these parameters without transfusions or growth factors.

Time frame:
Up to 17 months
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsIdelalisib + RituximabPlacebo + Rituximab
Overall Response Rate74.5 (65.4 to 82.4)14.5 (8.5 to 22.5)
SecondaryLymph Node Response Rate

Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the SPD of index lymph nodes.

Time frame:
Up to 17 months
Reported as:
Number · percentage of participants
Lymph Node Response Rate
percentage of participantsIdelalisib + RituximabPlacebo + Rituximab
Lymph Node Response Rate92.2 (85.1 to 96.6)5.9 (2.2 to 12.5)
SecondaryOverall Survival

Overall survival was defined as the interval from randomization to death from any cause.

Time frame:
Up to 17 months
Reported as:
Median · months
Overall Survival
monthsIdelalisib + RituximabPlacebo + Rituximab
Overall SurvivalNA (NA to NA)NA (12.8 to NA)
Statistical analysis
  • Idelalisib + Rituximab vs Placebo + Rituximab · Hazard ratio (hr): 0.28 · 95% CI 0.11 to 0.69
SecondaryComplete Response Rate

Complete response rate was defined as the percentage of participants who achieved a complete response.

Time frame:
Up to 17 months
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsIdelalisib + RituximabPlacebo + Rituximab
Complete Response Rate00

Adverse events

Collected over During study treatment plus 30 days (up to 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Rituximab—65/110 (59.1%)103/110 (93.6%)
Placebo + Rituximab—43/108 (39.8%)102/108 (94.4%)
Most frequent serious events
Showing 10 of 124
Most frequent serious events
EventIdelalisib + RituximabPlacebo + Rituximab
PneumoniaInfections and infestations13/11010/108
PyrexiaGeneral disorders10/1103/108
DiarrhoeaGastrointestinal disorders8/1100/108
SepsisInfections and infestations7/1103/108
Febrile neutropeniaBlood and lymphatic system disorders5/1106/108
CellulitisInfections and infestations1/1104/108
ColitisGastrointestinal disorders4/1100/108
Pneumocystis jirovecii pneumoniaInfections and infestations4/1101/108
PneumonitisRespiratory, thoracic and mediastinal disorders4/1101/108
AstheniaGeneral disorders2/1103/108
Most frequent other events
Showing 10 of 48
Most frequent other events
EventIdelalisib + RituximabPlacebo + Rituximab
PyrexiaGeneral disorders40/11018/108
FatigueGeneral disorders34/11035/108
CoughRespiratory, thoracic and mediastinal disorders27/11034/108
Infusion related reactionInjury, poisoning and procedural complications21/11033/108
DiarrhoeaGastrointestinal disorders31/11019/108
NauseaGastrointestinal disorders30/11025/108
NeutropeniaBlood and lymphatic system disorders28/11021/108
ChillsGeneral disorders27/11016/108
DyspnoeaRespiratory, thoracic and mediastinal disorders17/11022/108
Decreased appetiteMetabolism and nutrition disorders18/11012/108

Baseline characteristics

ITT Analysis Set: randomized participants with treatment group designated according to initial randomization.

Age, Continuous
Age, Continuous(years)Idelalisib + RituximabPlacebo + RituximabTotal
Mean71 ± 7.770 ± 8.171 ± 7.9
Age, Customized
Age, Customized(participants)Idelalisib + RituximabPlacebo + RituximabTotal
< 65 years212748
≥ 65 years8983172
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + RituximabPlacebo + RituximabTotal
Female344276
Male7668144
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Idelalisib + RituximabPlacebo + RituximabTotal
Hispanic or Latino325
Not Hispanic or Latino101102203
Not Permitted6612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Idelalisib + RituximabPlacebo + RituximabTotal
White10098198
Black or African American336
Other224
Not Permitted5712
Region of Enrollment
Region of Enrollment(participants)Idelalisib + RituximabPlacebo + RituximabTotal
France336
Germany7512
Italy257
United Kingdom181432
United States8083163
Karnofsky Performance Status
Karnofsky Performance Status(participants)Idelalisib + RituximabPlacebo + RituximabTotal
40112
50347
606511
70201333
80424688
90232851
100151328
Time Since Diagnosis
Time Since Diagnosis(months)Idelalisib + RituximabPlacebo + RituximabTotal
Mean108.3 ± 62.28106.4 ± 52.73107.4 ± 57.58

2 further baseline measures are reported on the registry.

08

Study locations

72 sites
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • University of California, San Diego- Moores Cancer Center
    La Jolla, California 92093, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • UCLA
    Santa Monica, California 90404, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Rocky Mountain Blood and Marrow Transplant Program
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Georgetown University Medical Center Lombardi Cancer Center
    Washington, District of Columbia 20057, United States
  • Collaborative Medical Research Corporation
    Boynton Beach, Florida 33435, United States
  • Collaborative Research Group LLC
    Boynton Beach, Florida 33435, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Florida Cancer Specialists
    Saint Petersburg, Florida 33705, United States
  • Winship Cancer Institute at Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hematology Oncology Associates of Northern New Jersey
    Morristown, New Jersey 07962, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York 11042, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Willamette Valley Cancer Center
    Springfield, Oregon 97477, United States
  • Northwest Cancer Specialists, PC
    Tualatin, Oregon 97062, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Care Network of South Texas
    San Antonio, Texas 78217, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc
    Roanoke, Virginia 24014, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1024, United States
  • Yakima Valley Memorial Hospital / North Star Lodge
    Yakima, Washington 98902, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Hôpital Henri Mondor
    Creteil, 94010, France
  • Centre Hospitalier Régional Universitaire de Lille (CHRU)
    Lille, 59045, France
  • Hôpital Emile Muller
    Mulhouse, 68100, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Hôpital Pontchaillou
    Rennes, 35019, France
  • Centre Henri Becquerel
    Rouen, 76038, France
  • Hopital Purpan
    Toulouse, 31059, France
  • Gemeinschaftspraxis Hämatologie-Onkologie
    Dresden, 1307, Germany
  • Internistische Gemeinschaftspraxis
    Erlangen, 91052, Germany
  • Universitätsklinikum Köln
    Köln, 50937, Germany
  • Stauferklinikum Schwäb. Gmünd
    Mutlangen, 73557, Germany
  • Hämatologische/Onkologische Gemeinschaftspraxis Dr. Peter Schmidt / Dr. Holger Klaproth
    Neunkirchen, 66538, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Ospedale Oncologico Regionale A. Businco
    Cagliari, 9121, Italy
  • Ospedale San Raffaele S.r.l.
    Milano, 20132, Italy
  • Azienda Ospedaliera Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • Royal Bournemouth Hospital
    Bournemouth, BH7 7DW, United Kingdom
  • Addenbrooke's Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • University Hospital of Wales
    Cardiff, CF14 4XW, United Kingdom
  • Castle Hill Hospital
    Cottingham, HU10 6ED, United Kingdom
  • Dorset County Hospital
    Dorchester, DT1 2JY, United Kingdom
  • Western General Hospital
    Edinburgh, EH4 2XU, United Kingdom
  • Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L7 8XP, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • Sarah Cannon Research Institute UK
    London, W1G 6AD, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Princess Royal University Hospital
    Orpington, BR6 8ND, United Kingdom
  • Salisbury District Hospital
    Salisbury, SP2 8BJ, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
  • Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
  • Great Western Hospital
    Swindon, SN3 6BB, United Kingdom
  • Torbay District General Hospital
    Torquay, TQ2 7AA, United Kingdom
  • Royal Cornwall Hospital
    Truro, TR1 3LJ, United Kingdom
  • New Cross Hospital
    Wolverhampton, WV10 0QP, United Kingdom
  • Yeovil District Hospital
    Yeovil, BA21 4AT, United Kingdom
09

References and documents

Publications

  • Barrientos JC, Hillmen P, Salles G, Sharman J, Stilgenbauer S, Gurtovaya O, Xing G, Ruzicka B, Bhargava P, Ghia P, Pagel JM. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leuk Lymphoma. 2021 Apr;62(4):837-845. doi: 10.1080/10428194.2020.1845339. Epub 2020 Dec 10. PubMed 33297794 ↗
  • Gordon MJ, Huang J, Chan RJ, Bhargava P, Danilov AV. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. 2021 Feb;192(4):720-728. doi: 10.1111/bjh.16879. Epub 2020 Jun 29. PubMed 32599655 ↗
  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 Mar 13;370(11):997-1007. doi: 10.1056/NEJMoa1315226. Epub 2014 Jan 22. PubMed 24450857 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2012
First posted
Feb 27, 2012
Start
Apr 2012
Primary completionActual
Oct 2013
CompletionActual
Apr 2014
Results first posted
Oct 16, 2014
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01539512
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 27, 2012
Start date
Apr 2012
Primary completion
Oct 2013
Completion
Apr 2014
Results posted
Oct 16, 2014
Last update
May 14, 2019

Study contacts

Thomas Jahn, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion